EZN 4176

Drug Profile

EZN 4176

Alternative Names: EZN416; RNA antagonist of the androgen receptor

Latest Information Update: 05 Dec 2014

Price : $50

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Androgen receptor antagonists; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone cancer; Prostate cancer

Most Recent Events

  • 16 Oct 2014 Discontinued - Preclinical for Bone cancer in USA (IV)
  • 28 Oct 2013 Enzon Pharmaceuticals terminates its licence for EZN 4176
  • 17 Dec 2012 Suspended - Phase-I for Prostate cancer in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top